Prof. Pauline Rudd PhD, MA(Oxon),B.Sc,L.R.I.C.


Professor Pauline Rudd (NIBRT Research Professor of Glycobiology) heads a research group in the National Institute for Bioprocessing Research and Training (NIBRT) and is currently located in the Conway Institute at UCD. Funded by the government, through the IDA, to the tune of €72m, NIBRT’s research strategy is focused on the design, development and optimisation of bioprocesses for the safe and economic manufacture of biopharmaceuticals.

The basic research programme deals with biomarkers for disease, especially cancer, and the underlying mechanisms that result in glycosylation changes. The novel analytical strategies developed by the group enable the sensitive, robust, detailed high-throughput analysis required for both the biomarker programme and the biopharmaceutical industry.Professor Rudd moved to Ireland in 2006 following the decision of the Glycan Sequencing Group at the Glycobiology Institute, Oxford, to relocate to Dublin. The setting up of the NIBRT was seen as an opportunity for Oxford to have its cutting edge technology applied in a new way which would place Ireland at the centre of the European Pharmaceutical Industry.

Prof. Rudd was a Founding Scientist of Wessex Biochemicals (Sigma London), Visiting Research Associate at The Scripps Research Institute, CA, Visiting Professor of Biochemistry at Shanghai Medical University PRC, Visiting Scientist at Ben Gurion University of the Negev, Israel and an Erskine Visiting Fellow, Canterbury University, Christchurch, New Zealand.

She was recently a University Reader in Glycobiology and Senior Research Fellow in the Glycobiology Institute, Oxford and is currently an Honorary Professor at St. George’s Hospital London and an adjunct Professor at the Barnett Institute, North Eastern University, Boston, USA.


For further information »

Recent Publications

  1. Shahrokh, Z., Royle, L. et al. Erythropoietin Produced in a Human Cell Line (Dynepo) Has Significant Differences in Glycosylation Compared with Erythropoietins Produced in CHO Cell Lines. Mol Pharm., 2011, ASAP.
  2. von der Lieth, C. W.; Arda Freire, A. et al. EUROCarbDB: An open-access platform for glycoinformatics. Glycobiology, 2011, ASAP.
  3. Arnold, J. N.; Saldova, R. et al. Novel Glycan Biomarkers for the Detection of Lung Cancer. J Proteome Res., 2011, ASAP.
  4. Bones, J.; Byrne, J. C. et al. Glycomic and Glycoproteomic Analysis of Serum from Patients with Stomach Cancer Reveals Potential Markers Arising from Host Defense Response Mechanisms. J Proteome Res., 2011, ASAP.
  5. Saldova, R.; Fan, Y. et al. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology, 2011, 21(2):195-205.
  6. Artemenko, N.V.; Campbell, M.P.; Rudd, P.M.: GlycoExtractor: a web-based interface for high throughput processing of HPLC-glycan data. J Proteome Res., 2010, 9(4):2037-41.
  7. Ahn, J.; Bones, J. et al. Separation of 2-aminobenzamide labeled glycans using hydrophilic interaction chromatography columns packed with 1.7 microm sorbent. J Chromatogr B, 2010, 878(3-4): 403-8.
  8. Barrabes, S.; Sarrats, A. et al. Effect of sialic acid content on glycoprotein pI analyzed by two-dimensional electrophoresis. Electrophoresis, 2010, 31(17): 2903-2912.
  9. Bones, J.; Mittermayr, S. et al. Ultra performance liquid chromatographic profiling of serum N-glycans for fast and efficient identification of cancer associated alterations in glycosylation. Anal Chem, 2010, 82(24): 10208-15.
  10. Coman, D. J.; Murray, D. W. et al. Galactosemia, a single gene disorder with epigenetic consequences. Pediatr Res, 2010, 67(3): 286-92.
  11. Ercan, A.; Cui, J. et al. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum, 2010, 62(8): 2239-48.
  12. Harvey, D. J.; Jaeken, J. et al. Fragmentation of negative ions from N-linked carbohydrates, part 4. Fragmentation of complex glycans lacking substitution on the 6-antenna. J Mass Spectrom, 2010, 45(5): 528-35.
  13. Harvey, D. J. and Rudd, P. M. Identification of by-products formed during the release of N-glycans with protein N-glycosidase F in the presence of dithiothreitol. J Mass Spectrom, 2010, 45(7): 815-9.
  14. Knezevic, A., Gornik, O. et al. Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans. Glycobiology, 2010, 20(8): 959-69.
  15. Lauc, G., Essafi, A. et al. Genomics meets glycomics-the first GWAS study of human N-Glycome identifies HNF1alpha as a master regulator of plasma protein fucosylation. PLoS Genet, 2010, 6(12): e1001256.
  16. Lauc, G., Rudan, I. et al. Complex genetic regulation of protein glycosylation. Mol Biosyst, 2010, 6(2): 329-35.
  17. Liu, L., Telford, J. E. et al. High-throughput glycoanalytical technology for systems glycobiology. Biochem Soc Trans, 2010, 38(5): 1374-7.
  18. Marino, K., Bones, J., Kattla, J.J. et al. A systematic approach to protein glycosylation analysis: a path through the maze. Nat Chem Biol, 2010, 6(10): 713-23.
  19. McVicar, C. M.; Colhoun, L. M. et al. Differential modulation of angiogenesis by erythropoiesis-stimulating agents in a mouse model of ischaemic retinopathy. PLoS One, 2010, 5(7): e11870-1 - e11870-16.
  20. Montesino, R.; Gil, J. et al. The N-glycosylation of classical swine fever virus E2 glycoprotein extracellular domain expressed in the milk of goat. Arch Biochem Biophys, 2010, 500(2): 169-80.
  21. Muindi, K.; Cernadas, M. et al. Activation state and intracellular trafficking contribute to the repertoire of endogenous glycosphingolipids presented by CD1d. Proc Natl Acad Sci U S A. 2010, 107(7):3052-7.
  22. Peracaula, R.; Sarrats, A. et al. Liver proteins as sensor of human malignancies and inflammation. Proteomics Clin Appl, 2010, 4(4): 426-31.
  23. Pierce, A.; Saldova, R. et al. Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patients. Glycobiology, 2010, 20(10): 1283-8.
  24. Pucic, M.; Pinto, S. et al. Common aberrations from the normal human plasma N-glycan profile. Glycobiology, 2010, 20(8): 970-5.
  25. Ritchie, G.; Harvey, D.J. et al. Identification of N-linked carbohydrates from severe acute respiratory syndrome (SARS) spike glycoprotein. Virology. 2010 Apr 10;399(2):257-69.
  26. Ritchie, G.; Harvey, D.J. et al. Identification of N-glycans from Ebola virus glycoproteins by matrix-assisted laser desorption/ionisation time-of-flight and negative ion electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom. 2010, 24(5):571-85.
  27. Saldova, R., Fan, Y. et al. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology, 2010, 21(2): 195-205.
  28. Saldova, R.; Reuben, J. M. et al. Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts. Ann Oncol, 2010, mdq570
  29. Sarrats, A.; Saldova, R. et al. Glycan Characterization of PSA 2-DE Subforms from Serum and Seminal Plasma. OMICS, 2010, 14(4): 465-74.
  30. Sarrats, A.; Saldova, R. et al. Glycosylation of liver acute-phase proteins in pancreatic cancer and chronic pancreatitis. Proteomics Clin Appl, 2010, 4(4): 432-48.
  31. Stanta, J. L.; Saldova, R. et al. Identification of N-glycosylation changes in the CSF and serum in patients with schizophrenia. J Proteome Res, 2010, 9(9): 4476-89.
  32. Tharmalingam, T., Marino, K. et al. Platform technology to identify potential disease markers and establish heritability and environmental determinants of the human serum N-glycome. Carbohydr Res, 2010, 345(10): 1280-2.
  33. Triguero, A.; Cabrera, G. et al. Chemical and enzymatic N-glycan release comparison for N-glycan profiling of monoclonal antibodies expressed in plants. Anal Biochem, 2010, 400(2): 173-83.
See all publications